Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCN NASDAQ:IMA NASDAQ:OKYO NASDAQ:SCLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$3.50-3.3%$3.32$1.03▼$8.48$15.68M1.7419,369 shs73,378 shsIMAImageneBio$5.59+0.4%$5.76$3.94▼$18.00$59.56M0.739,846 shs9,244 shsOKYOOKYO Pharma$1.55+4.7%$1.58$1.34▼$3.35$62.86M0.06171,437 shs45,727 shsSCLXScilex$6.84-7.4%$7.59$4.20▼$34.27$58.08M1.66197,159 shs128,884 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics-3.31%-3.85%+11.46%+19.05%+16.67%IMAImageneBio+0.36%+3.90%-6.83%-2.10%-66.24%OKYOOKYO Pharma+4.73%+8.39%0.00%-3.73%-44.44%SCLXScilex-7.44%-18.96%-0.29%+2.24%-39.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$3.50-3.3%$3.32$1.03▼$8.48$15.68M1.7419,369 shs73,378 shsIMAImageneBio$5.59+0.4%$5.76$3.94▼$18.00$59.56M0.739,846 shs9,244 shsOKYOOKYO Pharma$1.55+4.7%$1.58$1.34▼$3.35$62.86M0.06171,437 shs45,727 shsSCLXScilex$6.84-7.4%$7.59$4.20▼$34.27$58.08M1.66197,159 shs128,884 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics-3.31%-3.85%+11.46%+19.05%+16.67%IMAImageneBio+0.36%+3.90%-6.83%-2.10%-66.24%OKYOOKYO Pharma+4.73%+8.39%0.00%-3.73%-44.44%SCLXScilex-7.44%-18.96%-0.29%+2.24%-39.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCNCyclerion Therapeutics 1.00SellN/AN/AIMAImageneBio 2.00Hold$30.00436.67% UpsideOKYOOKYO Pharma 2.40Hold$5.67265.59% UpsideSCLXScilex 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CYCN, OKYO, IMA, and SCLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026OKYOOKYO Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/13/2026OKYOOKYO Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $5.006/29/2026IMAImageneBio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/16/2026SCLXScilex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/11/2026IMAImageneBio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderperform4/29/2026CYCNCyclerion Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCNCyclerion Therapeutics$1.99M7.60N/AN/A$2.31 per share1.52IMAImageneBioN/AN/AN/AN/A$11.91 per shareN/AOKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/ASCLXScilex$30.25M1.92N/AN/A($24.94) per share-0.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCNCyclerion Therapeutics-$3.53M-$1.36N/AN/AN/A-170.11%-62.10%-55.14%8/4/2026 (Estimated)IMAImageneBio-$45.35M-$5.79N/AN/AN/AN/A-38.96%-34.60%N/AOKYOOKYO Pharma-$4.71MN/AN/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)SCLXScilex-$358.73M-$40.47N/AN/AN/A-1,110.17%N/A-143.55%9/2/2026 (Estimated)Latest CYCN, OKYO, IMA, and SCLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026N/ACYCNCyclerion Therapeutics-$7.10N/AN/AN/A$1.50 millionN/A5/20/2026Q1 2026SCLXScilex-$0.3373-$4.76-$4.4227-$6.28$15.00 million$8.61 million5/12/2026Q1 2026CYCNCyclerion Therapeutics-$17.20-$0.76+$16.44-$0.76$0.88 millionN/A5/7/2026Q1 2026IMAImageneBio-$0.70-$0.95-$0.25-$0.95N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AIMAImageneBioN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCNCyclerion TherapeuticsN/A1.801.80IMAImageneBioN/A18.3918.39OKYOOKYO PharmaN/AN/AN/ASCLXScilexN/A0.080.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCNCyclerion Therapeutics75.62%IMAImageneBio75.00%OKYOOKYO Pharma2.97%SCLXScilex69.67%Insider OwnershipCompanyInsider OwnershipCYCNCyclerion Therapeutics34.30%IMAImageneBio2.22%OKYOOKYO Pharma40.46%SCLXScilex4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCNCyclerion Therapeutics304.33 million2.85 millionNo DataIMAImageneBio7010.65 million10.42 millionNot OptionableOKYOOKYO Pharma740.56 million24.15 millionNot OptionableSCLXScilex808.49 million8.11 millionNo DataCYCN, OKYO, IMA, and SCLX HeadlinesRecent News About These CompaniesScilex Announces Strategic Sale of Vivasor Preferred SharesJuly 22 at 6:11 PM | tipranks.comScilex Holding CompanyJuly 16, 2026 | cnn.comScilex (NASDAQ:SCLX) Trading Up 0.8% - Here's What HappenedJuly 10, 2026 | marketbeat.comSemnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for ...July 7, 2026 | finance.yahoo.comSemnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLPJuly 7, 2026 | globenewswire.comScilex Holding Company (SCLX) Stock Surges on $100M Investment Proposal from iHoldingJuly 6, 2026 | blockonomi.comScilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026July 6, 2026 | globenewswire.comScilex shares jump after securing $100 million strategic investment proposal (SCLX)July 6, 2026 | msn.comWhat's going on with Scilex Holding stock Monday?July 6, 2026 | msn.comScilex secures major growth capital equity investmentJuly 6, 2026 | tipranks.comScilex Holding Company Announces Binding Term Sheet for $100 Million Strategic Investment from iHolding Group LLPJuly 6, 2026 | quiverquant.comQScilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLPJuly 6, 2026 | globenewswire.comScilex Pursues Major Bitcoin Acquisition via Term SheetJune 29, 2026 | tipranks.comScilex Stockholders Approve Director Election and Equity PlanJune 24, 2026 | tipranks.comScilex Holding Company to List Dream Bowl Tokens on Biconomy Exchange Starting June 23, 2026June 16, 2026 | quiverquant.comQScilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026June 16, 2026 | globenewswire.comScilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders ...June 12, 2026 | finance.yahoo.comScilex Holding Company Announces Dividend Payment Date for Semnur Pharmaceuticals Common StockJune 12, 2026 | quiverquant.comQScilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity SecuritiesJune 12, 2026 | globenewswire.comScilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of ...June 5, 2026 | theglobeandmail.comScilex Holding Company ("Scilex") Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of ...June 4, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNextEra’s Dominion Deal Could Put It at the Center of the AI Power RaceBy Nathan Reiff | June 30, 20262 Quantum Stocks That Could Challenge IonQ’s LeadershipBy Nathan Reiff | July 15, 2026SpaceX Achieves Escape Velocity With Nasdaq Fast-TrackBy Jeffrey Neal Johnson | June 30, 2026General Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsBy Thomas Hughes | July 2, 2026BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings AloneBy Chris Markoch | June 26, 2026CYCN, OKYO, IMA, and SCLX Company DescriptionsCyclerion Therapeutics NASDAQ:CYCN$3.50 -0.12 (-3.31%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$3.48 -0.02 (-0.43%) As of 07/24/2026 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.ImageneBio NASDAQ:IMA$5.59 +0.02 (+0.36%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$5.60 +0.01 (+0.18%) As of 07/24/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.OKYO Pharma NASDAQ:OKYO$1.55 +0.07 (+4.73%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.56 +0.00 (+0.32%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Scilex NASDAQ:SCLX$6.84 -0.55 (-7.44%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$6.96 +0.12 (+1.78%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
